VTVT — vTv Therapeutics Inc
NASDAQ · Healthcare · Biotechnology
$31.95
-$0.05 (-0.16%)
vTv Therapeutics Inc (VTVT) is a biotechnology company listed on NASDAQ. It is led by Paul J. Sekhri, based in 3980 Premier Drive, High Point, NC, United States, 27265, with about 26 employees. vTv Therapeutics Inc., a late-stage biopharmaceutical company, focuses on developing oral small molecule drug candidates intended to treat people living with diabetes and other chronic diseases. Its lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial to treat type 1 diabetes. The company is also investing a range of molecules across various indications for chronic diseases. It has a license agreement Newsoara Biopharma Co., Ltd. to develop and commercialize phosphodiesterase type 4 inhibitors program. vTv Therapeutics Inc. was incorporated in 2015 and is headquartered in High Point, North Carolina.
Latest reported VTVT revenue for 2025-09-30 was $0. Net income was -$10.3M. VTVT currently screens at market cap $133.9M.
Use this VTVT page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the VTVT quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the VTVT SEC filings page. Lician reads the product cache first so this HTML stays unique to vTv Therapeutics Inc even when a live quote feed is slow.
About vTv Therapeutics Inc
vTv Therapeutics Inc., a late-stage biopharmaceutical company, focuses on developing oral small molecule drug candidates intended to treat people living with diabetes and other chronic diseases. Its lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial to treat type 1 diabetes. The company is also investing a range of molecules across various indications for chronic diseases. It has a license agreement Newsoara Biopharma Co., Ltd. to develop and commercialize phosphodiesterase type 4 inhibitors program. vTv Therapeutics Inc. was incorporated in 2015 and is headquartered in High Point, North Carolina.
VTVT Key Statistics
Market Cap
$133.91M
Volume
9,413
Previous Close
$33.89
Day Range
$33.50 – $34.51
P/B Ratio
1.49
EPS
$0.00
Revenue
$1.02M
Net Income
-$22.70M
Gross Profit
$0.00
Free Cash Flow
$0.00
Profit Margin
-2232.5%
Employees
26
VTVT Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $1.02M | $0.00 | $2.02M | $4.00M |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$22.70M | -$25.97M | -$25.07M | -$17.73M |
| EPS (Diluted) | $0.00 | $0.00 | $0.00 | $0.00 |
Total Assets
$38.27M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$36.75M
Operating Cash Flow
-$25.31M
Free Cash Flow
$0.00
vTv Therapeutics Inc Company Information
- CEO, President & Chairman of the Board
- Paul J. Sekhri
- Headquarters
- 3980 Premier Drive, High Point, NC, United States, 27265
- Website
- vtvtherapeutics.com
- Phone
- 336 841 0300
- IPO / Founded
- 2015-07-30
- Sector
- Healthcare
- Industry
- Biotechnology